These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 16036024)

  • 1. Interactions between the sympathetic nervous system and the RAAS in heart failure.
    Goldsmith SR
    Curr Heart Fail Rep; 2004 Jul; 1(2):45-50. PubMed ID: 16036024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of RAAS inhibitors for the treatment of heart failure].
    Murohara T
    Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G; Bhat G
    Cardiol Clin; 2014 Feb; 32(1):21-32, vii. PubMed ID: 24286576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination Therapy of Renin Angiotensin System Inhibitors and β-Blockers in Patients with Heart Failure.
    Nochioka K; Sakata Y; Shimokawa H
    Adv Exp Med Biol; 2018; 1067():17-30. PubMed ID: 29542073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship of the sympathetic nervous system and the renin-angiotensin system in congestive heart failure.
    Francis GS
    Am Heart J; 1989 Sep; 118(3):642-8. PubMed ID: 2570521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future.
    Orsborne C; Chaggar PS; Shaw SM; Williams SG
    Postgrad Med J; 2017 Jan; 93(1095):29-37. PubMed ID: 27671772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?
    Werner C; Pöss J; Böhm M
    Drugs; 2010 Jul; 70(10):1215-30. PubMed ID: 20568830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple renin-angiotensin-aldosterone-blocking agents in heart failure: how much is too much?
    Pitt B
    Curr Heart Fail Rep; 2009 Jun; 6(2):112-6. PubMed ID: 19486595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Miller AB; Srivastava P
    Cardiol Clin; 2001 May; 19(2):195-202, v. PubMed ID: 11407105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What constitutes optimal neurohumoral antagonism in chronic heart failure?
    Tajik AA; Dickstein K
    Heart; 2016 Dec; 102(23):1922-1932. PubMed ID: 27742799
    [No Abstract]   [Full Text] [Related]  

  • 12. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of recent clinical trials in heart failure: what is the current standard of care?
    Murray DR; Dugan J
    Cardiol Rev; 2000; 8(6):340-7. PubMed ID: 11208254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications.
    Triposkiadis F; Karayannis G; Giamouzis G; Skoularigis J; Louridas G; Butler J
    J Am Coll Cardiol; 2009 Nov; 54(19):1747-62. PubMed ID: 19874988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives.
    Kjaer A; Hesse B
    Clin Physiol; 2001 Nov; 21(6):661-72. PubMed ID: 11722473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel blockers of the renin-angiotensin-aldosterone system in chronic heart failure.
    Valluri A; Struthers AD; Lang CC
    Curr Heart Fail Rep; 2014 Mar; 11(1):31-9. PubMed ID: 24234398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the renin-angiotensin-aldosterone system in diastolic heart failure: potential for pharmacologic intervention.
    Bernal J; Pitta SR; Thatai D
    Am J Cardiovasc Drugs; 2006; 6(6):373-81. PubMed ID: 17192127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic management of heart failure: neurohormonal agents.
    Moser DK
    Crit Care Nurs Clin North Am; 1993 Dec; 5(4):599-608. PubMed ID: 7905275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of RAAS--when is it too much?
    Navarro P; Moskowitz R; Le Jemtel TH
    Curr Heart Fail Rep; 2004 Jul; 1(2):57-64. PubMed ID: 16036026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: what we know and current controversies.
    Moser DK; Biddle MJ
    Crit Care Nurs Clin North Am; 2003 Dec; 15(4):423-37, vii-viii. PubMed ID: 14717387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.